| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Interleukin-2 and regulatory T cells in graft-versus-host disease.
|
N Engl J Med
|
2011
|
6.02
|
|
2
|
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
|
JAMA
|
2009
|
4.08
|
|
3
|
Cord colitis syndrome in cord-blood stem-cell transplantation.
|
N Engl J Med
|
2011
|
3.83
|
|
4
|
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
|
Blood
|
2004
|
3.61
|
|
5
|
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
|
Biol Blood Marrow Transplant
|
2007
|
3.58
|
|
6
|
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
|
Blood
|
2002
|
3.56
|
|
7
|
Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome.
|
N Engl J Med
|
2013
|
3.39
|
|
8
|
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
|
N Engl J Med
|
2013
|
3.27
|
|
9
|
Contribution of bone marrow-derived endothelial cells to human tumor vasculature.
|
Nat Med
|
2005
|
3.19
|
|
10
|
Rituximab for steroid-refractory chronic graft-versus-host disease.
|
Blood
|
2006
|
3.08
|
|
11
|
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
|
Blood
|
2011
|
3.02
|
|
12
|
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
|
Blood
|
2004
|
2.89
|
|
13
|
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
|
Lancet Oncol
|
2011
|
2.78
|
|
14
|
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
|
Blood
|
2011
|
2.66
|
|
15
|
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
|
Blood
|
2005
|
2.65
|
|
16
|
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
|
Blood
|
2007
|
2.57
|
|
17
|
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
|
Blood
|
2007
|
2.54
|
|
18
|
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
|
Blood
|
2009
|
2.50
|
|
19
|
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
|
J Clin Oncol
|
2008
|
2.44
|
|
20
|
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast.
|
Plast Reconstr Surg
|
2011
|
2.43
|
|
21
|
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
|
Blood
|
2011
|
2.41
|
|
22
|
Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2002
|
2.40
|
|
23
|
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
|
Blood
|
2003
|
2.36
|
|
24
|
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
|
Blood
|
2008
|
2.35
|
|
25
|
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
|
Blood
|
2011
|
2.33
|
|
26
|
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
|
Blood
|
2004
|
2.30
|
|
27
|
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
|
Blood
|
2010
|
2.17
|
|
28
|
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
29
|
The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2008
|
2.09
|
|
30
|
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.
|
Blood
|
2011
|
2.03
|
|
31
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
32
|
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
|
J Clin Invest
|
2010
|
2.00
|
|
33
|
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
|
Clin Cancer Res
|
2007
|
2.00
|
|
34
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
35
|
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2006
|
1.99
|
|
36
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.95
|
|
37
|
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.
|
Blood
|
2005
|
1.95
|
|
38
|
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
1.91
|
|
39
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
40
|
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
|
Biol Blood Marrow Transplant
|
2011
|
1.88
|
|
41
|
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
|
Biol Blood Marrow Transplant
|
2009
|
1.87
|
|
42
|
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.84
|
|
43
|
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.
|
J Exp Med
|
2004
|
1.84
|
|
44
|
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
|
Blood
|
2004
|
1.82
|
|
45
|
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
|
Blood
|
2003
|
1.79
|
|
46
|
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
|
Blood
|
2002
|
1.79
|
|
47
|
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
|
Biol Blood Marrow Transplant
|
2010
|
1.76
|
|
48
|
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.72
|
|
49
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.72
|
|
50
|
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
|
Blood
|
2008
|
1.71
|
|
51
|
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
1.70
|
|
52
|
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
|
Biol Blood Marrow Transplant
|
2008
|
1.69
|
|
53
|
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
|
J Clin Oncol
|
2012
|
1.68
|
|
54
|
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.
|
J Clin Oncol
|
2009
|
1.65
|
|
55
|
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
|
Blood
|
2004
|
1.58
|
|
56
|
Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.
|
J Clin Oncol
|
2002
|
1.55
|
|
57
|
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
|
Am J Hematol
|
2010
|
1.54
|
|
58
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
|
Biol Blood Marrow Transplant
|
2009
|
1.53
|
|
59
|
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.
|
Blood
|
2010
|
1.50
|
|
60
|
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
|
Blood
|
2002
|
1.49
|
|
61
|
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
|
Biol Blood Marrow Transplant
|
2012
|
1.48
|
|
62
|
Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
1.48
|
|
63
|
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.
|
Blood
|
2004
|
1.47
|
|
64
|
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.
|
Blood
|
2007
|
1.44
|
|
65
|
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
|
Biol Blood Marrow Transplant
|
2005
|
1.44
|
|
66
|
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
|
Blood
|
2008
|
1.42
|
|
67
|
Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.
|
Biol Blood Marrow Transplant
|
2008
|
1.41
|
|
68
|
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.
|
Nat Genet
|
2009
|
1.40
|
|
69
|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
|
Biol Blood Marrow Transplant
|
2010
|
1.39
|
|
70
|
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
|
J Clin Invest
|
2014
|
1.38
|
|
71
|
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
|
Biol Blood Marrow Transplant
|
2010
|
1.34
|
|
72
|
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
|
Proc Natl Acad Sci U S A
|
2009
|
1.34
|
|
73
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
74
|
Evidence for ineffective erythropoiesis in severe sickle cell disease.
|
Blood
|
2005
|
1.31
|
|
75
|
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
|
J Clin Invest
|
2013
|
1.30
|
|
76
|
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.
|
Blood
|
2003
|
1.29
|
|
77
|
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.27
|
|
78
|
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
1.27
|
|
79
|
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
|
Biol Blood Marrow Transplant
|
2009
|
1.23
|
|
80
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
81
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
82
|
Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation.
|
Blood
|
2002
|
1.14
|
|
83
|
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
|
Blood
|
2013
|
1.14
|
|
84
|
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.13
|
|
85
|
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
|
Biol Blood Marrow Transplant
|
2009
|
1.13
|
|
86
|
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
|
Blood
|
2009
|
1.12
|
|
87
|
A survey of diagnosis, management, and grading of chronic GVHD.
|
Biol Blood Marrow Transplant
|
2002
|
1.11
|
|
88
|
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
|
Clin Cancer Res
|
2004
|
1.11
|
|
89
|
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
90
|
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
91
|
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2013
|
1.08
|
|
92
|
Optimistic expectations and survival after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2003
|
1.08
|
|
93
|
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.
|
Biol Blood Marrow Transplant
|
2013
|
1.07
|
|
94
|
Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
|
Biol Blood Marrow Transplant
|
2007
|
1.07
|
|
95
|
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
|
Transfusion
|
2009
|
1.06
|
|
96
|
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.06
|
|
97
|
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
98
|
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
|
Blood
|
2011
|
1.05
|
|
99
|
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.
|
Blood
|
2002
|
1.04
|
|
100
|
The clinical spectrum of acute graft-versus-host disease.
|
Semin Hematol
|
2006
|
1.04
|
|
101
|
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.
|
Cancer Discov
|
2011
|
1.02
|
|
102
|
Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.01
|
|
103
|
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
|
Blood
|
2003
|
1.01
|
|
104
|
A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation.
|
Blood
|
2002
|
1.01
|
|
105
|
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.01
|
|
106
|
Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
|
Curr Opin Hematol
|
2010
|
1.01
|
|
107
|
Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome.
|
Cancer
|
2004
|
1.00
|
|
108
|
Donor leukocyte infusions in myeloid malignancies: new strategies.
|
Best Pract Res Clin Haematol
|
2006
|
1.00
|
|
109
|
Ocular graft-versus-host disease: a review.
|
Surv Ophthalmol
|
2013
|
1.00
|
|
110
|
Does iron overload really matter in stem cell transplantation?
|
Am J Hematol
|
2012
|
0.99
|
|
111
|
Donor-derived second hematologic malignancies after cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.98
|
|
112
|
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.
|
Br J Haematol
|
2007
|
0.96
|
|
113
|
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2013
|
0.96
|
|
114
|
Current and future approaches for control of graft-versus-host disease.
|
Expert Rev Hematol
|
2008
|
0.95
|
|
115
|
CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD.
|
Blood
|
2003
|
0.95
|
|
116
|
Symptoms of pain and depression in related marrow donors: changes after transplant.
|
Psychosomatics
|
2003
|
0.95
|
|
117
|
Mental status changes after hematopoietic stem cell transplantation.
|
Cancer
|
2009
|
0.94
|
|
118
|
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.94
|
|
119
|
Predictors of 1-year survival assessed at the time of bone marrow transplantation.
|
Psychosomatics
|
2004
|
0.93
|
|
120
|
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2002
|
0.93
|
|
121
|
Allogeneic stem cell transplantation for aplastic anemia.
|
Biol Blood Marrow Transplant
|
2007
|
0.92
|
|
122
|
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
|
Biol Blood Marrow Transplant
|
2010
|
0.92
|
|
123
|
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
|
J Infect Dis
|
2013
|
0.92
|
|
124
|
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.
|
Haematologica
|
2010
|
0.92
|
|
125
|
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.
|
Transplantation
|
2011
|
0.91
|
|
126
|
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
|
Clin Cancer Res
|
2010
|
0.91
|
|
127
|
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.90
|
|
128
|
Psychosocial function after hematopoietic stem cell transplantation.
|
Psychosomatics
|
2005
|
0.89
|
|
129
|
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
|
Blood
|
2011
|
0.88
|
|
130
|
Chronic graft-versus-host disease.
|
Curr Opin Oncol
|
2006
|
0.87
|
|
131
|
An overview of hematopoietic stem cell transplantation.
|
Clin Chest Med
|
2005
|
0.87
|
|
132
|
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.
|
Blood
|
2002
|
0.86
|
|
133
|
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
|
Ther Adv Hematol
|
2012
|
0.84
|
|
134
|
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
|
Exp Hematol
|
2008
|
0.84
|
|
135
|
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.
|
Biol Blood Marrow Transplant
|
2010
|
0.83
|
|
136
|
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
137
|
Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
|
Transplantation
|
2002
|
0.82
|
|
138
|
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
|
Biol Blood Marrow Transplant
|
2012
|
0.82
|
|
139
|
Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
|
Respir Med
|
2012
|
0.81
|
|
140
|
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
|
Am J Hematol
|
2014
|
0.81
|
|
141
|
Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
|
Am J Drug Alcohol Abuse
|
2010
|
0.81
|
|
142
|
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.
|
Transfusion
|
2004
|
0.80
|
|
143
|
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
|
Am J Hematol
|
2014
|
0.80
|
|
144
|
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
|
Biol Blood Marrow Transplant
|
2007
|
0.79
|
|
145
|
Biology and management of acute graft-versus-host disease.
|
Cancer Treat Res
|
2009
|
0.79
|
|
146
|
Invasive fungal disease after remote inoculation in transplant recipients.
|
Clin Infect Dis
|
2011
|
0.79
|
|
147
|
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
|
Am J Hematol
|
2014
|
0.79
|
|
148
|
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
|
Biol Blood Marrow Transplant
|
2010
|
0.79
|
|
149
|
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
|
Cancer
|
2004
|
0.77
|
|
150
|
Novel drugs for the prevention and treatment of acute GVHD.
|
Curr Pharm Des
|
2008
|
0.77
|
|
151
|
Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome.
|
J Neuropsychiatry Clin Neurosci
|
2014
|
0.77
|
|
152
|
Outcomes and management strategies for graft failure after umbilical cord blood transplantation.
|
Am J Hematol
|
2014
|
0.76
|
|
153
|
Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient.
|
Nat Clin Pract Nephrol
|
2006
|
0.76
|
|
154
|
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
155
|
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
|
Curr Hematol Malig Rep
|
2006
|
0.75
|
|
156
|
The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.75
|
|
157
|
American journal of cancer research: editorial board (2011).
|
Am J Cancer Res
|
2011
|
0.75
|